← Back to Search

Procedure

Hysteroscopic Morcellation for Uterine Fibroids

N/A
Waitlist Available
Led By Magdy P Milad, MD, MA
Research Sponsored by Northwestern University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, an average of 1 year

Summary

This trial compares two pressure settings (60 mmHg vs. 80 mmHg) for a device used to remove uterine fibroids during hysteroscopy. It aims to find out which pressure setting provides better visualization and outcomes for patients undergoing this procedure.

Eligible Conditions
  • Uterine Fibroids

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Amount of Fluid
Change in pressure was needed
Lasix administered post-operatively
+3 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: 60 mmHg MyoSure Hysteroscopic Morcellator DeviceActive Control1 Intervention
The rationale for this experimental arm is that the pressurization can result in excess fluid being absorbed by the patient without a substantial benefit to surgical outcome. Minimizing the pressure from 80 mmHg (which is standard of care) to 60 mmHg used during this procedure may optimize outcome without compromising visualization of the surgeon. The research procedure will take place in the operating room of the minimally invasive gynecologic surgery department.
Group II: 80 mmHg MyoSure Hysteroscopic Morcellator DevicePlacebo Group1 Intervention
This is the standard of care pressurization for this procedure at Northwestern Medicine and will be the control group for the study

Find a Location

Who is running the clinical trial?

Northwestern UniversityLead Sponsor
1,647 Previous Clinical Trials
958,455 Total Patients Enrolled
Magdy P Milad, MD, MAPrincipal InvestigatorNorthwestern University
Magdy P Milad, MD, MMPrincipal InvestigatorNorthwestern University

Media Library

MyoSure Hysteroscopic Morcellator Device (Procedure) Clinical Trial Eligibility Overview. Trial Name: NCT04550429 — N/A
Uterine Fibroids Research Study Groups: 60 mmHg MyoSure Hysteroscopic Morcellator Device, 80 mmHg MyoSure Hysteroscopic Morcellator Device
Uterine Fibroids Clinical Trial 2023: MyoSure Hysteroscopic Morcellator Device Highlights & Side Effects. Trial Name: NCT04550429 — N/A
MyoSure Hysteroscopic Morcellator Device (Procedure) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04550429 — N/A
~7 spots leftby Nov 2025